Top Tweets for #BioTechs
Bringing a new #therapy to market requires immense #expertise, #infrastructure, and #capital. Consequently, #biotechs increasingly leverage strategic #outsourcing as a core pillar of modern drug development. More details here: https://t.co/yzcAuesswr
@Biorasi is bringing confident #clinicaltrials to #BIOInternational this month.
Let's connect in San Diego to explore what success means for today's #biotechs, plus our new AI-powered study strategy tool - #BiorasiHive.
Schedule a 1-on-1 meeting >> https://t.co/h3b9t1UJS2
$XBI #Biotechs elevated M&A activity to continue in 2026 given 23 blockbuster
drugs, representing nearly $150bn in 2025 sales, are expected to go off-patent by 2030.
tailwind for valuations &view macro-related selloffs, especially in fundamentally-
sound revenue generating companies, as potential opportunities for strategics to step in
$XBI #Biotechs BofA Biotech M&A streak continues; $66bn through 1H
biotech sector continues to see deal-seeking appetite in 2Q, with 6 acquisitions of
US-listed public biotech companies for a combined $32bn in deal value-followed a strong 2026 start during which 8 deals were announced in 1Q for a combined
$34bn in deal value.
$XBI #Biotechs BofA Biotech M&A streak continues; $66bn through 1H
biotech sector continues to see deal-seeking appetite in 2Q, with 6 acquisitions of
US-listed public biotech companies for a combined $32bn in deal value-followed a strong 2026 start during which 8 deals were announced in 1Q for a combined
$34bn in deal value.
$XBI #Biotechs #Profitability nice to see very different Biotech sector gaining traction - profitability $LQDA $TGTX $AXSM $TARS
$XBI #Biotechs - Josh Schimmer blurb today This is a very different biotech sector than we've had in the past, with a growing and critical mass of successful product launches and companies transitioning to profitability. There are always ups & downs and streakiness in the industry, but Biotech's never been in such a strong position fundamentally, and remain constructive on the sector.👍
@RaasGroup has published an update on immuno oncology group @TeamImugene $IMU following several ASX announcements over the past month. Our $0.24/share rNPV remains unchanged representing 252% potential capital upside. #lifesciences #biotechs #asxbiotechs #progress
$MLYS Still listening but I like this guy from MLYS. This company is ready to be in the hands of BP-all opex easily synergized. Pleasantly surprised by the directness of questions and the way MLYS answered all of them.
$AXSM Jefferies $AXSM stock should climb to $200-225/sh following Auvelity's (oral NMDA)
label expansion in Alz agitation (AADAD), which boosts combined peak sales
towards $3-4B+ (e.g. $2-3B in MDD depression, $1B+ AADAD). No surprises in
the label. expect a launch by Q2:26-end. Auvelity should be differentiated
from Rexulti (an oral antipsychotic guided for $1B+ in AADAD), given a novel
MOA, rapid efficacy, and cleaner safety (e.g. no black box for increased
mortality).
$KRTL POSTS #biotech #Biotechnology #BIOTECHS $IKTO $CORT $MLGO $GATE $GDHG $IMTE $AMGN $REGN $MRNA $RPRX $META $GOOGL $MSFT $AMZN $NVDA $AAPL $RPRX $FBRX $DRUG $VRTX $REGN $IQV $UTHR $TECH $CRL $REGN $RPRX #CheapPharma
https://t.co/mYAiVlRozu
$KRTL Shareholder Update: Management is currently preparing several press releases covering key corporate developments and strategic initiatives. We appreciate your continued support and look forward to sharing additional updates as they become available. Stay tuned. #KRTL
$XBI #Biotechs Goldman 47th Annual Global Healthcare Conference will take place next week (June 8-10;
Miami Beach, FL Top 10 requested 1x1 meetings: $LLY, $AZN, $GILD, $REGN, $MDLN, $VRTX, $ALNY, ABBV,
$MRK, $JNJ
So die Rotation fängt langsam an - seid ihr schon korrekt positioniert? 🧐📉📈
#Healthcare #Biotechs $XLV $XBI #SectorRotation $SPY $SPX #Aktien #Finanzen #Börse #StockMarket
𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐤𝐨̈𝐧𝐧𝐭𝐞 𝐯𝐨𝐫 𝐝𝐞𝐫 𝐧𝐚̈𝐜𝐡𝐬𝐭𝐞𝐧 𝐠𝐫𝐨ß𝐞𝐧 𝐑𝐨𝐭𝐚𝐭𝐢𝐨𝐧 𝐬𝐭𝐞𝐡𝐞𝐧
Die letzten zwei Jahre wurden die Märkte von einer Handvoll MegaCaps getragen (z.B. Meta, Google, MSFT etc.).
Wenn nun Geld aus überlaufenen Tech-Positionen abfließt, werden oft andere Investmöglichkeiten gesucht z.B. Sektoren mit:
🔹niedrigeren Bewertungen
🔹stabileren Cashflows
🔹defensivem Charakter
🔹geringerem Intresse
Und hier kommt Healthcare - ein langweiliger Sektor ins Spiel.
⸻
Warum Healthcare aktuell interessant aussieht
Der Healthcare-Sektor (XLV) hat die KI- und Tech-Rally weitgehend verpasst.
Während viele Technologieaktien ATHs jagen, notiert der Healthcare Sektor im historischen Vergleich deutlich moderater.
Gleichzeitig bleibt der Sektor jedoch fundamental attraktiv:
🔹alternde Bevölkerung
🔹steigende Gesundheitsausgaben
🔹robuste Cashflows
Das macht den Healthcare Sektor zu einem perfekten Kandidaten für eine Marktrotation.
Vor allem wenn man die Marktzyklen berücksichtigt:
⸻
Die Elliott-Wellen-Struktur auf dem $XLV 3M-Chart deutet auf einen möglichen langfristigen Impuls hin.
Aktuell scheint sich eine größere Welle (4) ihrem Ende zu nähern.
Sollte diese Zählung korrekt sein, könnte anschließend die finale Welle (5) starten.
Mögliche Preisziele:
🔹 195 USD
🔹 212 USD
🔹 261 USD
Natürlich sind Elliott-Wellen keine Garantie, sondern lediglich ein Wahrscheinlichkeitsmodell.
DYOR!
Marktzyklen basierend auf https://t.co/ku3XgG1lPg
⸻
$XLV #Healthcare #Stocks #Investing #SectorRotation #ElliottWave #Trading #StockMarket #SP500 #Markets $XBI $PFE $MRNA $CLOV $UNH
$LQDA $TGTX $TARS & others #Biotechs that are all ready profitable imho deserve more premium on bio days like today
$XBI #Biotechs Cantor salute all the 'ASCO warriors' - the oncology innovators&investors who spend their time wading through the endless abstracts, posters and presentations to make heads & tails of the very competitive space.
Biotech - so now what? The $XBI got caught in the 120-130 trading range from November to April and now has toggled up to the 130-140 trading range. We're picking up cautious optimism from investors
$VKTX 1.8 Billion in sales in 2030 per Truist $XBI #Biotechs
$VKTX Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled --
-- Initiation of Phase 3 Oral VK2735 Trial for Obesity Expected 4Q26 --
-- VK2735 Maintenance Dosing Study Ongoing; Data Expected 3Q26 --
-- IND Filed for Novel Amylin Agonist VK3019; Phase 1 Trial Initiation Expected 2Q26 --
-- Strong Quarter-End Cash Position of $603 Million -
@POTUS @SecKennedy @houmanhemmati @DrOz @DrPatrick @KerriHT
Small innovative #Biotechs are left LAST at the nefarious hands of the #FDA #BigPharma
Same ol’ story #MAHA #RareDisease #CNPV delay, block, reject, require new trial etc.
* Clear disparity!
$OCGN $IBRX $QURE $NWBO
Rare disease patients? Ignored, and promising treatments blocked by FDA under Marty Makary. This great piece by my friend @PeterPitts calls for new leadership to open doors and windows to rare disease. Yes, please. @realDonaldTrump @POTUS
https://t.co/pLsrXVr13f
$XBI #Biotechs GS Big Picture: Biotechnology outperformed the broader markets this week (XBI/NBI
+1.64%/+2.16 vs. the S&P 500 +0.88%), continuing to be driven by geopolitical conflict
dynamics which fueled sector rotations. Biotech remains fundamentally strong on 1Q earnings execution, M&A outlook,&catalysts, noting the $XBI (+8%) is
the top performer in healthcare YTD.
$PTGX Nice to see analyst /research who understands $PTGX research/development Playforms - simply under appreciated but one of best in #biotechs
$PTGX WolfeResearch initiated coverage $PTGX) at an Outperform rating $135PT
“We Like The ICOnomics” ability to achieve clinical proof of concept (PoC) earlier than most.
Rather underappreciated for PTGX is the catalyst-rich period it is entering argue that PTGX can exit 2026 at $135 (+34% upside). With valuation asymmetrically skewed positive, be buyers at these levels.
Last Seen Hashtags on Sotwe
SRIAYUTARISA
Seen from United States
ometvterbaru
Seen from Indonesia
OTD
Seen from United States
ShareYourWeather
Seen from United States
MistressFanny
Seen from Israel
nolimit() https
Seen from Pakistan
Amatuerteen
Seen from Brazil
petite
Seen from Turkey
HARDBODY
Seen from Jordan
欅坂46暗黒時代
Seen from Indonesia
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
240.2M followers
Barack Obama
@barackobama
119.3M followers
Donald J. Trump
@realdonaldtrump
111.6M followers
Cristiano Ronaldo
@cristiano
109.5M followers
Narendra Modi
@narendramodi
106.9M followers
Rihanna
@rihanna
97.4M followers
NASA
@nasa
92.1M followers
Justin Bieber
@justinbieber
90.7M followers
KATY PERRY
@katyperry
87.1M followers
Taylor Swift
@taylorswift13
80.9M followers
Lady Gaga
@ladygaga
72.5M followers
Kim Kardashian
@kimkardashian
69.5M followers
Virat Kohli
@imvkohli
69M followers
YouTube
@youtube
68.6M followers
Bill Gates
@billgates
63.5M followers
The Ellen Show
@theellenshow
62.5M followers
CNN
@cnn
61.9M followers
Neymar Jr
@neymarjr
61.6M followers
X
@x
60.9M followers
Selena Gomez
@selenagomez
60.2M followers